Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Not Applicable

Completed

• Conditions: Hyperuricemia; Hemodialysis Complication

• Registration Number: NCT03149939
• Lead Sponsor: Benha University

Brief Summary

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01-01
• Primary Completion: 2017-04-01
• Status Verified: 2017-05
• Study Completion: 2017-05-01
• Study First Submitted: 2017-05-10
• Study First Submitted QC: 2017-05-10
• Last Update Submitted: 2017-05-10
• Study First Posted: 2017-05-11
• Last Update Posted: 2017-05-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Age above 18 years
• Hemodialysis patient
• Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

Exclusion Criteria

• Patient currently and/or recently received drugs for hyperuricemia within the last three months
• Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Change in serum uric acid	at three months of Febuxostat 40 milligrams Tablet therapy	Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy